AstraZeneca Pharma India gets marketing nod for cancer drug Tagrisso
Osimertinib has shown to decrease the chances of cancer spreading to the brain & other distant organs.;
Bangalore: Drug maker, AstraZeneca Pharma India Limited, has recently announced that it has received marketing approval for Tagrisso (Osimertinib) for adjuvant treatment after complete tumour resection in patients with non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations
According to the Global Cancer Survey (GLOBOCAN), in 2018, the total number of new Lung cancer cases were 67,795 & 63,475 deaths were reported, making lung cancer a very aggressive and devastating cancer. It has also been estimated that by 2020, India would have around ~ 89,000 new Lung Cancer cases.
The main reason for this increase in death rates with Lung Cancer is due to the fact that close to 80%-90% of Lung Cancer cases are detected and diagnosed in the late stage, where the 5 years survival rate is less than 5%.
To increase the survival rates in Lung cancer, it is very important to diagnose and treat lung cancer in early stages before the cancer has spread to other parts of the body. However, even by providing the best treatment in early stages like surgery and post-surgery chemotherapy in eligible patients, more than half of the patients have a disease/cancer recurrence within 5 years. This is mainly attributed to the fact that cancer tends to recur again & there have been very few advances in treatment of Early Stage Lung Cancer. This represents a unmet need in management of patients in an effort to increase their survival rates
Read also: AstraZeneca gets CDSCO nod for Dapagliflozin in CKD
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.